Skip to main content

Table 2 Recently published clinical studies of three leading hemoglobin-based oxygen carriers

From: Hemoglobin-based oxygen carriers

  Product name
Details PolyHeme® Hemopure® (HBOC-201) HemoLink™ (Hb-raffimer)
Company Northfield Laboratories (Evanston, IL, USA) Biopure Corporation (Cambridge, MA, USA) Hemosol Inc. (Ontario, Canada)
Indicated use Trauma/urgent surgery Cardiac surgery Coronary artery bypass graft
Clinical trial status Phase III Phase III Phase II/III
Study design Multicenter, randomized, double blind Multicenter, randomized, double blind Multicenter, randomized, single blind
End-point Mortality Transfusion avoidance Transfusion avoidance
Major findings PolyHeme increased survival Hemopure reduced allogeneic red cell transfusion HemoLink reduced allogeneic red cell transfusion
Current status Phase III mortality study Filed BLA Clinical study suspended pending further analysis
Reference Gould and coworkers [11] Levy and coworkers [12] Hill and coworkers [19]
  1. BLA, Biologic License Application.